Literature DB >> 34181680

Real-time computer-aided diagnosis of focal pancreatic masses from endoscopic ultrasound imaging based on a hybrid convolutional and long short-term memory neural network model.

Anca Loredana Udriștoiu1, Irina Mihaela Cazacu2, Lucian Gheorghe Gruionu3, Gabriel Gruionu3,4, Andreea Valentina Iacob1, Daniela Elena Burtea2, Bogdan Silviu Ungureanu2, Mădălin Ionuț Costache2, Alina Constantin5, Carmen Florina Popescu6, Ștefan Udriștoiu1,7, Adrian Săftoiu2,5.   

Abstract

Differential diagnosis of focal pancreatic masses is based on endoscopic ultrasound (EUS) guided fine needle aspiration biopsy (EUS-FNA/FNB). Several imaging techniques (i.e. gray-scale, color Doppler, contrast-enhancement and elastography) are used for differential diagnosis. However, diagnosis remains highly operator dependent. To address this problem, machine learning algorithms (MLA) can generate an automatic computer-aided diagnosis (CAD) by analyzing a large number of clinical images in real-time. We aimed to develop a MLA to characterize focal pancreatic masses during the EUS procedure. The study included 65 patients with focal pancreatic masses, with 20 EUS images selected from each patient (grayscale, color Doppler, arterial and venous phase contrast-enhancement and elastography). Images were classified based on cytopathology exam as: chronic pseudotumoral pancreatitis (CPP), neuroendocrine tumor (PNET) and ductal adenocarcinoma (PDAC). The MLA is based on a deep learning method which combines convolutional (CNN) and long short-term memory (LSTM) neural networks. 2688 images were used for training and 672 images for testing the deep learning models. The CNN was developed to identify the discriminative features of images, while a LSTM neural network was used to extract the dependencies between images. The model predicted the clinical diagnosis with an area under curve index of 0.98 and an overall accuracy of 98.26%. The negative (NPV) and positive (PPV) predictive values and the corresponding 95% confidential intervals (CI) are 96.7%, [94.5, 98.9] and 98.1%, [96.81, 99.4] for PDAC, 96.5%, [94.1, 98.8], and 99.7%, [99.3, 100] for CPP, and 98.9%, [97.5, 100] and 98.3%, [97.1, 99.4] for PNET. Following further validation on a independent test cohort, this method could become an efficient CAD tool to differentiate focal pancreatic masses in real-time.

Entities:  

Year:  2021        PMID: 34181680     DOI: 10.1371/journal.pone.0251701

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  5 in total

Review 1.  Artificial intelligence-assisted endoscopic ultrasound in the diagnosis of gastrointestinal stromal tumors: a meta-analysis.

Authors:  Binglan Zhang; Fuping Zhu; Pan Li; Jing Zhu
Journal:  Surg Endosc       Date:  2022-09-13       Impact factor: 3.453

Review 2.  Diagnostic Value of Artificial Intelligence-Assisted Endoscopic Ultrasound for Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Elena Adriana Dumitrescu; Bogdan Silviu Ungureanu; Irina M Cazacu; Lucian Mihai Florescu; Liliana Streba; Vlad M Croitoru; Daniel Sur; Adina Croitoru; Adina Turcu-Stiolica; Cristian Virgil Lungulescu
Journal:  Diagnostics (Basel)       Date:  2022-01-25

Review 3.  Artificial Intelligence and Machine Learning in the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms-A Scoping Review.

Authors:  Athanasios G Pantelis; Panagiota A Panagopoulou; Dimitris P Lapatsanis
Journal:  Diagnostics (Basel)       Date:  2022-03-31

Review 4.  Enhanced endoscopic ultrasound imaging for pancreatic lesions: The road to artificial intelligence.

Authors:  Marco Spadaccini; Glenn Koleth; James Emmanuel; Kareem Khalaf; Antonio Facciorusso; Fabio Grizzi; Cesare Hassan; Matteo Colombo; Benedetto Mangiavillano; Alessandro Fugazza; Andrea Anderloni; Silvia Carrara; Alessandro Repici
Journal:  World J Gastroenterol       Date:  2022-08-07       Impact factor: 5.374

Review 5.  Application of artificial intelligence to pancreatic adenocarcinoma.

Authors:  Xi Chen; Ruibiao Fu; Qian Shao; Yan Chen; Qinghuang Ye; Sheng Li; Xiongxiong He; Jinhui Zhu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.